Report Code: LS10039 | Available Format: PDF
Infectious diseases are medical conditions or disorders caused by microorganisms such as bacteria, fungi, viruses and other parasites. Several organisms are present in and on human bodies. Some organisms are normally harmless and even helpful. However, under certain circumstances, some organisms cause diseases. Infectious diseases spread from one person to another. Moreover, some are transmitted by bites from insects and animals. Infectious diseases also occur by consumption of contaminated food and water.
Signs and symptoms of infectious diseases depend on the type of organism and infection. Some of the most common symptoms of infectious diseases include fatigue and fever. Mild complaints of infectious diseases treated from rest and home remedies, while some life-threatening infections require hospitalization. Infectious diseases, such chickenpox and measles are prevented by vaccination. Frequent and thorough hand-washing also protect human body from infectious diseases.
Moreover, anti-infective drugs play a vital role in the treatment of infectious diseases. Anti-infective drugs are used to kill and stop growth of microorganism. These drugs can act as a defense system for human body and neutralize the action of disease causative agents. Based on microorganism, anti-infective drugs are mainly categorized into antiviral, antibacterial, antifungal and antiparasitic drugs.
The global infectious disease treatment market is segmented into antibacterial drugs, antifungal drugs, antiviral drugs and antiparasitic drugs. Antibacterial drugs segment covers tetracyclines, beta-lactams, aminoglycosides, macrolides, phenicols, sulfonamides and quinolones. Antifungal segment includes azoles, echinodians, pyrimidines, polyenes and allylamines. Antiviral drugs segment covers HIV, hepatitis B and C treatment drugs.
North America dominates the global infectious disease treatment market followed by Europe. The U.S., followed by Canada, is the largest market for infectious disease treatment in the North American region. Key driving factor for infectious disease treatment market in the region is increasing research activities on various types of diseases. Germany, France and the U.K. are some of the largest markets for infectious diseases in Europe. However, Asia-Pacific represents the fastest growing region in the global infectious disease treatment market. This is due to minimal wages and availability of skilled professionals in the region. These factors attract drug manufacturing companies to invest in the Asian countries. In addition, in developing countries, such as China and India, government has launched several programs and initiatives to increase awareness about infectious diseases. China, Japan and India are largest infectious disease treatment markets in the region.
Increasing prevalence of the infectious diseases is key driving factor for the global infectious disease treatment market. Increasing awareness and extensive R&D drugs pipelines are also enhancing the growth of global infectious disease market. Moreover, introduction of novel drugs, such as direct-acting antivirals, boosts the growth of global infectious disease treatment market.
However, patent expiry of various major drugs and presence of generic drugs are key restraint of the global infectious disease treatment market. Stringent regulations and legislations and side-effects of anti-infective drugs also hinder the growth of global infectious disease treatment market. Rapid product launches and increasing mergers and acquisitions between drug manufactures are emerging trends of the global infectious disease treatment market.
Some of the major competitors in the global infectious disease treatment market are F. Hoffmann-La Roche, GlaxoSmithKline, Merck, Johnson & Johnson, Pfizer, Gilead Sciences, Bristol-Myers Squibb Company, AstraZeneca, Bayer AG, Novartis, Sanofi, AbbVie and Auritec Pharmaceuticals.
Get a bespoke market intelligence solution
Our dedication to providing the most-accurate market information has earned us verification by Dun & Bradstreet (D&B). We strive for quality checking of the highest level to enable data-driven decision making for you
Our insights into the minutest levels of the markets, including the latest trends and competitive landscape, give you all the answers you need to take your business to new heights
With 24/7 research support, we ensure that the wheels of your business never stop turning. Don’t let time stand in your way. Get all your queries answered with a simple phone call or email, as and when required
We take a cautious approach to protecting your personal and confidential information. Trust is the strongest bond that connects us and our clients, and trust we build by complying with all international and domestic data protection and privacy laws